Melanoma and Kidney Cancer Group
Dr James Larkin's Group works to conceive and conduct clinical trials to increase understanding of the biology of these diseases and develop better treatments for them.
Research, projects and publications in this group
We are interested in how particular genetic changes and the order in which they happen impacts cancer progression, metastasis and treatment in both a clinical and translational setting.
Professor James Larkin
Honorary Faculty:
Melanoma and Kidney Cancer
Professor James Larkin is a Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of melanoma and kidney cancer, and a Reader at the ICR.
Researchers in this group
.
Professor James Larkin's group have written 608 publications
Most recent new publication 5/2025
See all their publicationsWe conduct both clinical and translational research.
In the translational setting we study genetic changes in melanoma and kidney cancers and their interaction with the cancer environment, in particular the immune system.
We are interested in how particular genetic changes and the order in which they happen impacts cancer progression, metastasis and treatment. We are tracking these changes in the blood to find out if they reflect what is happening at the level of the tumour.
Ultimately we want to translate these observations into clinical applications that help us manage our patients.
The group is pursuing a number of projects:
- Understanding Renal Cancer Evolution
- Understanding Melanoma
- Tracking cancer evolution in the patient’s blood
- Understanding the mechanisms of immunotherapy toxicity
Recent discoveries from this group
International trial shows combination immunotherapy treatment significantly improves survival in high-risk kidney cancer patients
ICR researchers named among world’s most influential scientists
